|
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 277, Issue 39, 36787-36792, September 27, 2002
From the Departments of
Received for publication, May 30, 2002, and in revised form, July 19, 2002
One mechanism by which nitric oxide (NO) has been
proposed to benefit patients with sickle cell disease is by reducing
intracellular polymerization of sickle hemoglobin (HbS). In this study
we have examined the ability of nitric oxide to inhibit polymerization by measuring the solubilizing effect of iron nitrosyl sickle hemoglobin (HbS-NO). Electron paramagnetic resonance spectroscopy was used to
confirm that, as found in vivo, the primary type of NO
ligation produced in our partially saturated NO samples is
pentacoordinate Sickle cell disease is caused by a mutation in the sixth codon of
the Nitric oxide is now being considered as a therapy for sickle cell
disease (5). During inhalation therapy, NO reacts with oxygenated Hb to
form methemoglobin (MetHb) and nitrate, with deoxygenated Hb (deoxyHb)
to form nitric oxide hemoglobin (HbNO), and a very small amount reacts
with the It is believed that only T-state HbS polymerizes (7, 8). Thus, at high
oxygen pressures, like those found at the lungs, HbS molecules are in
the R-state (high-affinity) and do not polymerize. In the tissues,
oxygen pressure is low, and polymerization becomes more likely. The
kinetics of polymerization have been described by an approximate,
empirical equation relating the delay time (the time during which
polymers are not detectable) to the supersaturation ratio (9) as shown
in Equation 1,
It has recently been proposed that nitric oxide (NO)
binding at the heme group to form iron nitrosylated HbS (HbS-NO) may also play a role in increasing HbS solubility in vivo
(10-13). Briehl and Salhany (14) found that tetranitrosyl hemoglobin (100% saturated HbS-NO) polymerizes in the presence of inositol hexaphosphate (IHP). However, stripped 100% tetranitrosyl did not
polymerize under the same conditions (14). Subsequently, McDade
et al. (11) reported preliminary results indicating that even small amounts of NO can substantially reduce polymerization in
purified HbS solutions and decrease sickling (12).
The difference in the effect of various ligands may be related to the
difference in their abilities to produce a T- to R-state transition
upon binding HbS. The quaternary state of nitrosyl hemoglobin has been
investigated using combinations of absorption, electron paramagnetic
resonance (EPR), and nuclear magnetic resonance (NMR) spectroscopies
(15-20). The quaternary state of tetranitrosyl hemoglobin favors the
R-state when it is stripped of organic phosphates such as
2,3-diphosphoglycerate (DPG) but favors the T-state in the presence of
IHP (18, 21). When nitrosyl hemoglobin is in the T-state, the
iron-proximal histidine bonds can break forming a pentacoordinate,
NO-bound heme. This pentacoordinate species is responsible for the
hyperfine splitting observed in EPR spectra. Thus EPR can be used to
probe the quaternary state of nitrosylated hemoglobin.
The pH, presence of organic phosphates and other solution conditions
have a large influence on the quaternary state of nitrosyl Hb (HbNO)
(18, 19). Since it is believed that only T-state HbS polymerizes, these
conditions could also greatly affect the solubility of HbS-NO. In
assessing the contribution the formation of HbS-NO may have in treating
patients with sickle cell disease, it should be remembered that only
very small amounts of NO can be administered (6). Yonetani et
al. (20) showed that when small amounts of NO are added to
deoxyHb, Unless otherwise noted, all reagents were obtained from Sigma
Chemical. Blood was obtained from patients with sickle cell disease
(SS) with low levels of fetal hemoglobin (HbF) who had not been
recently transfused following federal regulations and guidelines.
Electrophoresis was used to determine the levels of HbF (3.2 ± 2.1%) and HbA2 (5.0 ± 0.4%) in the samples. The
hemolysate was prepared from these samples within 24 h of drawing
as described previously (22). The samples were kept cold during all
preparatory procedures (on ice or at 4 °C).
Blood cells were washed in phosphate-buffered saline (PBS), pH 7.4 and
lysed by incubation in distilled water. The membranes were spun down,
and the hemolysate was then dialyzed against PBS buffer. Based on a
colorimetric assay (Sigma Chemical) we found that this procedure
results in a negligible change in the molar ratio of DPG to hemoglobin,
consistent with earlier results (23). Thus, the concentration of the
most physiologically relevant allosteric effector was the same for our
studies as that found in vivo. In some cases, when the
sample volume was slightly inadequate for an experiment, small amounts
of previously prepared hemolysate were used to increase the sample
volume. Those samples had been pelleted in liquid nitrogen for storage.
No effect of using the small amounts of previously frozen samples was
observed. The hemolysate was concentrated using Centriprep and
Centricon concentrating devices (Millipore, Bedford, MA) to a final
concentration of 16-19 mM (in heme). After purging the
samples with argon, sodium dithionite was added. Precautions in the
general handing of and preserving the anaerobicity of dithionite were
followed as described previously (24). Dithionite was placed in a
septum-capped bottle and purged with argon for about 2 h, after
which PBS buffer that had been bubbled with argon gas (also for about
2 h) was added to make a stock dithionite solution. This was then
added to the HbS sample that had been purged with argon to a final
concentration of 50 mM.
Iron nitrosyl hemoglobin was made by adding sodium nitrite to the
deoxygenated samples as described previously (25). A stock nitrite
solution was made and bubbled with argon gas. An aliquot of the stock
solution was added to the HbS sample that had been prepared with excess
sodium dithionite. The nitrite was reduced by dithionite to form NO,
which binds quickly to the hemoglobin, yielding nearly stochiometric
iron nitrosyl hemoglobin. This procedure was carried out within 1 h after addition of dithionite. We found that this method was superior
to exposing the hemoglobin directly to NO gas even when the system is
properly flushed with an inert gas, and the NO is passed through NaOH
to remove traces of higher nitrogen oxides (26). We found that it is
very difficult to remove all these unwanted nitrogen oxides and that we
often would have large concentrations of nitrite in our NO-saturated
buffer. Furthermore, we sometimes found a significant degree of protein denaturation when our Hb was exposed directly to NO gas. Finally, when
exposing Hb directly to NO gas it was not possible to control the
distribution of NO binding. One generally would need to make 100%
tetranitrosyl Hb and then mix this with deoxyHb to achieve a partially
saturated sample. If NO-saturated buffer is added directly to the Hb
sample, it will bind faster than the sample can be properly mixed. To
mimic in vivo conditions, where the concentration of NO is
small, it was desirable for us to be able to make HbS-NO samples
that had evenly distributed NO ligation. This is achievable using the
nitrite reduction method since the rate of this reaction was measured
to be 0.035 ± 0.007 1/s at 4 °C when using the same
concentrations of nitrite and dithionite as those used in preparing
HbS-NO for the solubility measurements. The rate was measured by
monitoring the formation of HbS-NO when Hb + dithionite was rapidly
mixed with sodium nitrite using an Olis RSM-1000 stopped-flow
spectrophotometer (Bogart, GA). By rigorously mixing nitrite solutions
directly to the Hb + dithionite solutions on ice, we could achieve
evenly distributed NO ligation. This is possible because the sample can
be thoroughly mixed before NO is released, so there is no extreme local
concentration of NO. If NO-saturated buffer is added to a hemoglobin
solution, the NO will react faster than the most rapid mixing technique and will thus form a larger quantity of tetranitrosyl hemoglobin. For
some experiments, nitrite was added in slight molar excess to Hb in
order to make 100% tetranitrosyl Hb. This was also occasionally then
diluted with deoxyHb for other experiments where we purposely made a
sample that was initially composed of a mixture of tetranitrosyl hemoglobin molecules and completely deoxygenated hemoglobin molecules.
The addition of dithionite resulted in a decrease in the pH of the PBS
buffer from 7.4 to 6.8. The presence of Hb or nitrite did not affect
the pH further as determined by a separate control experiment where we
added HbS and nitrite to a dithionite solution. Although this pH is
below physiological, it afforded us the possibility to work with
slightly lower Hb concentrations (due to the reduced solubility) and
thus conserve sickle cell blood. Furthermore, the same pH was used for
both the HbS-NO samples and deoxyHbS controls. No significant
difference in the type of iron nitrosyl ligation or the solubilizing
effect of NO on HbS was found when the experiments were repeated in a
Trizma buffer (pH 7.2 at 37 °C) with 0.1 M KCl and 0.02 M NaCl.
For each solubility measurement, deoxygenated HbS, nitrosylated
HbS, and other necessary materials were assembled in a dry hood
(model Dri Lab He-43-2, vacuum/atmosphere Corporation, Los Angeles,
CA). The atmosphere in the hood was cycled between vacuum and argon
several times before use. Inside the hood, the HbS-NO sample was
prepared along with a deoxygenated sample to be used as a control. The
HbS-NO sample and deoxyHb control were each then used to fill two
Quick-seal polyallomer ultracentrifuge tubes for the TLS-55 swinging
bucket rotor (Beckman Coulter Inc.), two 0.01-cm path length cells, and
two-0.1 cm path length cells (Hellma Inc., Plainview, NY). In
addition, a portion of the HbS-NO sample was always used to fill an EPR
tube (Wilmad/Lab Glass, Buena NJ, 701-PQ) and sometimes a second,
screw-cap EPR tube was filled (701-TR). Thus, for all experiments, we
were able to perform a variety of spectroscopic and other procedures on
identically prepared HbS-NO and deoxyHb samples.
The total concentration and percent of NO ligation was
determined using visible absorption spectroscopy on the 0.01-cm path length cells. The absorption spectra were fit to basis spectra normalized by their extinction coefficient using a least-squared minimization. The absence of any methemoglobin was also determined in
this way. The basis spectra used and a typical fit are shown in Fig.
1. The percentage of HbS-NO was also
determined by double integration of the EPR spectra (described in the
next paragraph). The difference in using these two methods was only
2.2 ± 2.0%. The values of Hb nitrosylation reported in the
results section are the averages of those determined by EPR and
absorption.
Electron paramagnetic resonance spectroscopy was conducted on a Bruker Electron Spin Resonance-ER-200 D Spectrometer with a B-VT 1000/ER 4111 VT variable temperature unit set at temperatures of 140 K using a 5-milliwatt microwave power, 5 G modulation amplitude, and 9.36 GHz microwave frequency. A 0.1-s time constant was used for 100-s scans over 500 G. The concentration of HbS-NO on samples that had previously been frozen in liquid nitrogen, was determined by double integration of the spectrum using EPRWare for Windows (Scientific Software Services, Normal, IL) and compared with a standard HbS-NO sample. The type of nitrosyl ligation was determined by fitting EPR spectra to
basis spectra shown in Fig. 2. These
three basis spectra, pentacoordinate
Linear dichroism (LD) spectroscopy was used to determine presence of HbS polymers in the 0.01-cm pathlength cells. The LD was measured on a LD/optical rotary dispersion (ORD) spectrometer developed by OLIS inc. (Bogart, GA). Light produced by a xenon lamp is sent through the patented rapid scanning monochromator that scans a spectrum every millisecond. The light then passes through a polarizer oriented at 45o with respect to the horizontal plane. After traversing the sample, the light passes through a photoelastic modulator (Hinds Instruments, Hillsboro, OR) and then through a beam-splitting polarizer producing horizontally and vertically polarized light. The two polarized beams are collected by two photomultiplier tubes and the difference divided by the sum of the intensities that is modulated by two times the reference frequency of the photoelastic modulator will be the ORD + LD. Since the ORD of hemoglobin is very small in the visible region, it can be ignored and any measured signal was attributed to LD of partially aligned sickle cell hemoglobin polymers. The delay time for polymerization was measured by observing the turbidity of the samples at 800 nm on either a PerkinElmer Lambda 9 spectrometer or a Cary 100 Bio UV/visible spectrometer. The samples were temperature jumped from 0 to 37 °C, and the turbidity was measured as a function of time. The samples were taken directly from ice to jacketed cell holders on the spectrophotometers. The temperature of the cells in the PerkinElmer machine was controlled by a Haake circulating bath (Paramus, NJ), and the temperature of the cells in the Cary machine was regulated by a Cary temperature controller. The centrifuge tubes were sealed in the dry hood and then incubated for
1 h at 37 °C to allow them to polymerize before measuring the
solubility by centrifugation. As with the delay time measurements, every experiment included a HbS-NO sample and a deoxygenated HbS control prepared in the same way as the HbS-NO sample except without the addition of nitrite. The samples were spun at 214,000 × g for 1 h at 37 °C as described previously (7). The
solubility was measured by determining the total concentration of
hemoglobin in the supernatant using absorption spectroscopy as
described above. LD was used to make sure that no polymers were present in the supernatant.
We found no evidence for polymerization of 100% tetranitrosyl HbS
from nine different preparations. Fig. 3
shows the absence of any LD for a 100% tetranitrosyl HbS sample. It is
compared with the LD of a deoxygenated sample and a partially
nitrosylated one. For the deoxyHbS and partially nitrosylated HbS
samples, one can flip the LD signal (as shown) by rotating the sample
about the axis defined by the incident light. The ability to flip the signal is strong evidence that it results from LD of partially aligned
polymers (27). Fig. 4 shows a typical
delay time measurement for a 100% tetranitrosyl sample compared with
that for a deoxyHbS sample prepared from the same hemolysate. No
polymerization is observed in the 100% tetranitrosyl sample.
Our solubility measurements also confirmed that 100% tetranitrosyl HbS is very soluble. If polymers are formed, the concentration in the supernatant following a sedimentation experiment should be equal to the solubility. When no polymers are formed, the concentration in the supernatant following sedimentation should be equal to the total concentration of HbS, and one can only say that the solubility is greater than or equal to the total concentration of the HbS. We found that the solubility of 100% tetranitrosyl HbS, prepared as a hemolysate in PBS buffer is greater than or equal to 19 mM. The solubility of partially ligated HbS-NO was measured for samples
prepared in two different ways. In one method, submolar amounts of
nitrite were added to HbS in the presence of dithionite. In the other
method, 100% tetranitrosyl HbS was diluted with deoxygenated HbS.
Although the first method should be able to achieve equally distributed
NO ligation, the faster off-rate from the
As discussed below, the solubility of 100% tetranitrosyl HbS is not likely to be important physiologically. However, its solubility is of general biochemical interest. We have found that it is very soluble. Briehl and Salhany (14) found no evidence that stripped 100% tetranitrosyl HbS can polymerize, even in pH 6 Tris buffer with a concentration of 30 mM at 20 °C. In the presence of IHP at pH 7.2, they found that the minimum gelling concentration of HbS was between 24 and 30 mM at 20 °C. Based on their results and the fact that IHP promotes polymerization more effectively than phosphate or DPG (28), one would predict that the solubility of 100% tetranitrosyl HbS in the presence of these physiologically relevant allosteric effectors would be between that of stripped HbS and that in the presence of IHP. Our results, using physiologically relevant concentrations of DPG, are consistent with this prediction. We have not seen evidence for polymerization of 100% tetranitrosyl HbS and have found the solubility to be greater than 19 mM. It is useful to compare the effect of NO (Fig. 6) on HbS solubility to
that of oxygen. In order to calculate the solubilizing effect of oxygen
we use empirical Equation 2 deduced by Eaton and Hofrichter (29),
-nitrosyl HbS during incubation at
37 °C regardless of how much HbS starts as tetranitrosyl. The
calculated solubilizing effect of a 26% oxygen-saturated HbS sample is
0.15. Thus, the solubilizing effect of NO is much less than that of
oxygen, contrary to earlier, preliminary reports (11, 12).
The poor solubilizing effect of NO can be partially attributed to its
inherently poor ability to effect a T- to R-state transition. Whereas
IHP can switch 100% tetranitrosyl hemoglobin from the R- to the
T-state it cannot do that for oxyhemoglobin or carbonmonoxyhemoglobin (17). In addition, it takes an average of 2.7 NO molecules to cause a
T- to R-state transition (30). When two NO molecules are bound to the
hemes of the The poor solubilizing effect can also be explained in terms of a poor
ability to form tetranitrosyl Hb, which would be R-state. For a Hb
sample that is 25% saturated with oxygen, 80% of the bound oxygen
will be to R4 molecules, 15% will be to R3
molecules, and 5% will be to T1 molecules, where the
subscripts indicate the degree of ligation for each quaternary state (R
or T) (31). Thus, in the case of oxygen, most of the oxygen will be
bound so as to effect a T- to R-state transition. The unequal
distribution of oxygen ligation is due to the larger affinity of
R-state Hb for oxygen compared with T-state. On the hand, unlike in the
case of oxygen, the rate of NO binding to Hb is not cooperative (30, 32, 33). Although the off-rate from T-state nitrosyl Hb is faster than
that from R-state (34, 35), the combination of the lack of
cooperativity in the NO-binding rate, together with a slower off-rate
from Our results strongly suggest that the direct solubilizing effect of NO
on HbS in vivo, whether produced endogenously or
therapeutically, is insignificant. Numerous studies have shown that
when HbNO is formed in vivo the primary product is
One might argue that the increased oxygen saturation in venous or
arterial circulation, compared with the conditions used here, would
lend HbS-NO a greater solubilizing effect by causing a T to R
conversion. However, Even if the solubilizing effect of HbS-NO were strong, the amount of
iron nitrosylation achievable through (for example) NO inhalation
therapy is less than 5 µM (6, 44). This small amount of
nitrosylation would need to have some sort of magical effect (compared
with oxygen) in order to have a significant effect in vivo.
NO therapy may also increase levels of SNO-Hb, where NO reacts with the
Based on our understanding of sickle cell pathophysiology one can envision several mechanisms by which NO administration might have beneficial effects on patient morbidity (5). These include reactions with sickle hemoglobin to alter its solubility or oxygen affinity, reactions with sickle erythrocytes to change cell volume and intracellular hemoglobin concentration, and effects on hemoglobin synthesis to change the intracellular hemoglobin composition, i.e. the ratio of sickle to non-sickle hemoglobins. At the physiological level, these include its strong direct effects on vascular tone in general, as well as effects on specific organs such as the pulmonary vessels. Less directly, the effects of NO on platelet aggregation and endothelial adhesion molecules might be beneficial by reducing components of the disease that appear similar to ischemia-reperfusion injury. We have found a negligible effect of nitrosylation on solubility. This result argues against reduced polymerization as a mechanism for increased oxygen affinity associated with exposure to NO suggested by Head et al. (10) and is consistent with Gladwin et al. (46) inability to observe such an increased oxygen affinity. If NO does increase the oxygen affinity of sickle cell hemoglobin as reported by Head et al. (10) but contested by Gladwin et al. (46), then our results suggest that it must do so via another mechanism than through a direct solubilizing effect. In conclusion, we have found that the direct solubilizing effect of
iron nitrosylation due to endogenous amounts of NO or NO produced by
inhalation therapy or other means is very likely to be negligible in
sickle cell patients. A role for NO-based therapies for sickle cell
disease based on vasodilation, anti-platelet, or anti-adhesive
activity, or hemoglobin F induction are being actively investigated
(5).
We thank Fouad Azizi for helpful discussion and technical assistance. The development of the LD/ORD spectrometer was supported by National Institutes of Health Grant RR15018 (to D. B. K.-S.).
* This work was supported by National Institutes of Health Grant HL58091 (to D. B. K.-S.) and the Wake Forest University Catalyst award (to D. B. K.-S. and S. B. K.). Additional support was obtained from the National Institutes of Health Grant HL62198 (to S. B. K.) and the Comprehensive Sickle Cell Center Program of the Commonwealth of Pennsylvania (to S. K. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Published, JBC Papers in Press, July 22, 2002, DOI 10.1074/jbc.M205350200
2
The solubilizing effect in the presence of
oxygen, SL', was estimated using data from Yonetani
et al. (20) on the relative oxygen affinity of
The abbreviations used are: Hb, hemoglobin; HbS, sickle hemoglobin; HbS-NO, iron-nitrosylated sickle hemoglobin; IHP, inositol hexaphosphate; DPG, 2,3-diphosphoglycerate; EPR, electron paramagnetic resonance; HbNO, iron-nitrosylated hemoglobin; deoxyHb, deoxygenated hemoglobin; HbF, fetal hemoglobin; PBS, phosphate-buffered saline; SNO-Hb, S-nitrosohemoglobin; MetHbS, oxidized sickle hemoglobin (methemoglobin); T-state Hb, the tense or taut quaternary structure of hemoglobin characterized by low oxygen affinity; R-state Hb, the relaxed quaternary structure of hemoglobin characterized by high oxygen affinity; LD, linear dichroism; ORD, optical rotary dispersion.
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc. This article has been cited by other articles:
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||